Table 8 Current ongoing early phase I/II trials with ROS1 inhibitors
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
ROS1 inhibitors | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
Ceritinib | ALK and ROS1 inhibitor | NCT03399487 (2) | Monotherapy | ROS 1 rearranged NSCLC |
Crizotinib | ALK, HGFR, C-Met and RON Inhibitor | NCT04084717 (2) | Monotherapy | NSCLC with ROS1 rearrangement or MET activating mutation/amplification |
Repotrectinib | ROS1/TRK inhibitor | NCT03093116 (2) | Monotherapy | ROS1/TRK altered NSCLC |
Lorlatinib | ALK and ROS1 inhibitor | NCT02927340 (2) | Monotherapy | ALK/ROS1 rearranged NSCLC with CNS disease |
Taletrectinib | ROS 1 and TRK fusion inhibitor | NCT04395677 (2) | Monotherapy | Advanced NSCLC with ROS1 fusion gene |